GlassScriptPhysician profile
Matthew Rutman
NPI 1083650170
$94,437.88
in general payments reported to CMS, 2019-2025
25 companies · $61.13 in 2025
The $61.13 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $8,173 · 2021: $11K · 2022: $12K · 2023: $12K · 2024: $11K · 2025: $61.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Consulting Fee: $9,500 · Travel and Lodging: $1,943 · Food and Beverage: $1,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,627.47 |
| Consulting Fee | $9,500.00 |
| Travel and Lodging | $1,943.33 |
| Food and Beverage | $1,314.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $49,026.39 | 2019-2022 | |
| Laborie Medical Technologies Corp. | $35,550.41 | 2021-2024 | |
| Ferring Pharmaceuticals INC. | $4,937.12 | 2019 | |
| Procept Biorobotics Corporation | $1,304.96 | 2019-2024 | Aquabeam Robotic System, Aquabeam System |
| Astellas Pharma US INC | $502.02 | 2019-2023 | Myrbetriq |
| Endo Pharmaceuticals INC. | $500.00 | 2023 | |
| C. R. Bard, INC. & Subsidiaries | $499.17 | 2021 | |
| Sumitomo Pharma America, INC. | $346.16 | 2023-2025 | Gemtesa |
| Medtronic USA, INC. | $235.31 | 2019-2020 | |
| Abbvie INC. | $225.73 | 2022-2024 | Botox |
| Allergan, INC. | $216.93 | 2019-2022 | |
| Axonics, INC. | $175.14 | 2022-2023 | Bulkamid |
| Neotract INC. | $151.32 | 2019 | |
| Coloplast Corp | $122.00 | 2019-2022 | |
| Hollister Incorporated | $111.86 | 2019-2023 | Infyna Chic, Vapro, Vapro Pocket |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $103.20 | 2023-2024 | Interstim |
| Dentsply Ih INC. | $92.16 | 2019 | |
| Janssen Biotech, INC. | $84.37 | 2022 | |
| Urovant Sciences INC | $80.59 | 2022 | |
| Urogen Pharma, INC. | $47.31 | 2024 | |
| Antares Pharma, INC. | $40.25 | 2021-2023 | Xyosted, Tlando, Nocdurna |
| Ambu INC. | $36.73 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $19.99 | 2019 | |
| 180 Medical, INC. | $16.83 | 2019 | |
| Pfizer INC. | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Rutman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.